PTAB Grants Celgene Rehearing In Cancer Drug Challenge
After ruling parts of two patents related to Celgene Corp.'s cancer drugs invalid, the Patent Trial and Appeal Board mostly stood by its original reasoning Friday, but granted a rehearing with...To view the full article, register now.
Already a subscriber? Click here to view full article